Daptomycin Inhibits Multiple Myeloma Progression through Downregulating the Expression of RPS19

Area of Science:

• Oncology
• Pharmacology
• Hematology

Background:

• Multiple myeloma (MM) is a prevalent plasma cell malignancy.
• Existing treatments for MM have limitations, necessitating novel therapeutic strategies.
• The anti-tumor potential of daptomycin (DAP) in MM is not well-established.

Purpose of the Study:

• To investigate the anticancer effects of daptomycin (DAP) on the RPMI 8226 multiple myeloma (MM) cell line.
• To elucidate the mechanism underlying DAP's potential anti-MM activity.

Main Methods:

• RPMI 8226 MM cells were treated with varying concentrations of DAP (20 μM, 40 μM, 80 μM).
• Bortezomib (BZ) was used as a positive control.
• Cell proliferation, apoptosis, cell cycle, migration, and invasion were assessed using CCK8, flow cytometry, and transwell assays.
• RPS19 mRNA and protein expression levels were analyzed.

Main Results:

• DAP significantly inhibited proliferation and induced apoptosis in MM cells.
• DAP treatment led to G1 phase cell cycle arrest.
• The migration and invasion capabilities of RPMI 8226 cells were reduced by DAP.
• DAP downregulated both mRNA and protein expression of RPS19 in MM cells.

Conclusions:

• Daptomycin exhibits significant anti-multiple myeloma effects by inhibiting proliferation, migration, and invasion, while promoting apoptosis.
• The observed anti-MM effects of DAP are associated with the downregulation of RPS19 expression.
• DAP represents a promising candidate for novel therapeutic drug development in multiple myeloma treatment.